drugset / Trial / NCT06158269
DVRd in the Treatment of Patients With Newly Diagnosed Double-hit Multiple Myeloma
NaSingle-groupOpen-labelTreatment
Summary
Evaluate the efficacy of DVRd in patients with newly diagnosed double-hit multiple myeloma (MM) and the feasibility of minimal residual disease (MRD) guided maintenance therapy
Timeline
- Start
- 2023-12
- Primary completion
- 2026-12
- Completion
- 2027-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bortezomib | Small molecule | — | — |
| Subject | Daratumumab | Monoclonal antibody | — | — |
| Subject | Dexamethasone | Small molecule | — | — |
| Subject | Lenalidomide | Other / unclassified | — | — |